Objective To investigate the association of nonsteroidal anti-inflammatory drug (NSAID) administration with urinary neutrophil gelatinase-associated lipocalin (NGAL) levels in children following cardiopulmonary bypass (CPB) who did not develop acute kidney injury (AKI).
When administered to children with decreased renal perfusion or cardiac output, NSAIDs can compromise renal blood flow and induce renal ischemia. 2 Children with congenital heart disease undergoing cardiopulmonary bypass (CPB) represent a population that may be at high risk for NSAID-induced acute kidney injury (AKI).
Neutrophil gelatinase-associated lipocalin (NGAL) is an early and sensitive urinary biomarker of AKI. 3 In children undergoing cardiac surgery, an elevated urine NGAL level 2 hours postoperatively can identify those who will develop AKI within 48 hours following CPB. 4, 5 As the field of urinary biomarkers continues to develop, the 10th Acute Dialysis Quality Initiative consensus conference proposed the use of urinary biomarkers to improve the evaluation and treatment of patients with AKI. Specifically, urinary biomarkers can provide both diagnostic and prognostic information independent of conventional markers such as serum creatinine, thereby refining the clinical management of AKI. 6 One application is in the field of nephrotoxicity, where urinary biomarkers such as NGAL may identify subclinical kidney injury, when structural damage occurs without the development of decreased kidney function (ie, a rise in serum creatinine). 7 In this study, we investigated the association of NSAID administration with urinary NGAL levels in a cohort of 210 children undergoing cardiac surgery with CPB who did not develop clinical AKI. We hypothesized that the children receiving NSAIDs would experience an increase in urinary NGAL concentration, indicating the presence of NSAID-induced subclinical kidney injury in this population. For this study, 158 children who developed AKI (defined as a 50% increase in serum creatinine from preoperative baseline values) within 72 hours following CPB were also excluded. The reason for this was 2-fold: (1) to remove the confounding presence of increased urinary NGAL levels due to AKI associated with CPB, and (2) to permit the evaluation of NSAID-induced subclinical kidney injury. Serum creatinine values were not routinely obtained after the study period, which extended up to 72 hours following CPB; therefore, patients may have developed AKI after this time point. Children who received angiotensin-converting enzyme inhibitors, aminoglycosides, or contrast agents (n = 57) postoperatively also were excluded, leaving a final cohort of 210. The primary predictor variable was NSAID administration, which was prescribed no sooner than 24 hours following CPB. The primary outcome variable was urine NGAL levels measured preoperatively and at 2, 6, 12, 24, 36, 48, and 72 hours following surgery.
AKI

Laboratory Analysis
Urine samples were obtained and stored in aliquots at −80°C before batch measurement. Urine NGAL was assayed using a commercially available enzyme-linked immunoassay (NGAL ELISA Kit 036; Bioporto, Grusbakken, Denmark) that specifically detects human NGAL. The intra-assay and interassay coefficients of variation were 2.1% and 9.1%, respectively.
Statistical Analyses
Descriptive analyses are reported as percentage for categorical variables and as median and IQR for continuous variables. Baseline characteristics were compared between those children who received NSAIDs and those who did not receive NSAIDs postoperatively. The c 2 test and Wilcoxon rank-sum test were used to compare between-group differences for categorical and continuous variables, respectively. NGAL levels were compared at each time point using the Wilcoxon ranksum test (between groups) and Wilcoxon signed-rank test (within the same group) as appropriate. A multivariable analysis was then performed to determine the independent association of NSAID exposure with urine NGAL level at each time point while adjusting for clinical characteristics. To account for the repeated nature of the data and within-subject correlation, generalized linear mixed modeling was used with study subject as a random effect. The association of NSAID use with serum NGAL level at each time point was investigated by including an interaction term (NSAID × time) in the model. NGAL levels were log-transformed to fulfill the assumptions of linear regression modeling. To determine the ability of urinary NGAL to identify children who received NSAIDs, conventional receiver operating characteristic (ROC) curve analyses were conducted. Area under the curve (AUC) values were calculated along with cutoff values resulting in 80% sensitivity. Corresponding specificity, positive predictive values, and negative predictive values also were reported at the specified cutoff value. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina).
Results
Of the 210 children included in the study, 146 (70%) received NSAIDs following cardiac surgery. Of those who received NSAIDs, 88% received multiple doses. Demographic, clinical, and laboratory characteristics of the study participants are summarized in Table I . The children who received NSAIDs were older and more likely to have undergone a previous surgery requiring CPB. Their cardiothoracic surgeries tended to have lower Risk Adjustment for Congenital Heart Surgery-1 scores with shorter CPB times. There were no between-group differences in sex, race, or baseline serum creatinine concentration.
As shown in Figure 1 , urine NGAL levels in all patients were low before surgery, ranging from 0 to 51 ng/mL. During the first 24 hours following CPB, during which no NSAIDs were administered to either group, no between-group differences in NGAL levels were evident. Both groups demonstrated a mild but significant rise in urine NGAL that peaked at 6 hours after surgery and then declined until 24 hours postsurgery. After 24 hours, when NSAIDs were administered, a divergence in urinary NGAL levels was observed. In those who received NSAIDs, the median urinary NGAL level increased from 15 ng/mL (IQR, 5-30 ng/mL) at 24 hours after CPB to 83 ng/mL (IQR, 45-95 ng/mL) at 72 hours after CPB (P < .001). In contrast, in the children who did not receive NSAIDs, the median NGAL level decreased from 15 ng/mL (IQR, 5-25 ng/mL) at 24 hours after CPB to 10 ng/mL (IQR, 5.4-15.9 ng/mL) at 72 hours after CPB (P = .01). In these children, urinary NGAL decreased to levels that were not significantly different from preoperative values. At all time points after 24 hours, urinary NGAL levels were significantly higher in the children who received NSAIDs (all P < .001). The association of urine NGAL level with NSAID administration was investigated at each time point in multivariable analysis (Table II) , adjusting for all of the clinical and demographic characteristics listed in Table I . NGAL level at 60-72 hours after CPB were more than 5-fold higher in the children who received NSAIDs compared with those who did not. To determine the ability of NGAL to identify patients who received NSAIDs, we performed ROC curve analyses for each time point starting at 36 hours after CPB. The median AUCs for urine NGAL at each time point were as follows: 36 hours, 0.88 (95% CI, 0.83-0.93); 48 hours, 0.95 (95% CI, 0.93-0.98); 60 hours, 0.96 (95% CI, 0.93-0.98); 72 hours, 0.96 (95% CI, 0.93-0.98). At 48 hours, an NGAL threshold of 39 ng/mL had a sensitivity of 81% and specificity of 98% to identify NSAID administration. Therefore, 118 of the 146 children who received NSAIDs had an NGAL level ≥39 ng/mL, compared with only 1 of 64 children who did not receive NSAIDs. The corresponding positive predictive value using this cutoff was 99%, with a negative predictive value of 69%.
To determine whether repeated doses of NSAIDs have a cumulative effect on increasing NGAL levels, we compared urinary NGAL levels between children receiving a single dose of NSAIDs (n = 18) and those receiving multiple doses of NSAIDs (n = 128). As shown in Figure 2 , NGAL levels increased from 24 to 48 hours following CPB in both groups; however, a divergent pattern of NGAL levels was observed after 48 hours, with levels decreasing in children receiving only 1 dose of NSAIDs but progressively increasing in those who continued to receive repeated doses. At 72 hours after CPB, the median NGAL level was 24.5 ng/mL (IQR, 15-33 ng/mL) in the children who received only 1 dose, compared with 85 ng/mL (IQR, 65-97.5 ng/mL) in those receiving multiple doses (P < .001). To determine the ability of NGAL to discriminate between 1 dose vs multiple NSAID doses, we performed ROC All variables in Table I were included as covariates in the multivariable analysis. Previous CPB was mildly significant (P = .04) and was associated with a mean increase in NGAL level of 23% (95% CI, 1%-50%). All other variables were not significant at the P < .05 level. 
Discussion
In this cohort of children undergoing cardiac surgery and CPB who did not develop clinical AKI, NSAID administration was associated with a significant increase in urinary NGAL levels. The increase in NGAL levels was first detected within 12 hours after NSAID administration, and levels remained persistently elevated in those who received repeated doses. These results indicate that NSAID use in critically ill children is associated with subclinical kidney injury that occurs despite normal kidney function. Identification of nephrotoxin-mediated kidney injury is an emerging application of urinary NGAL concentration. This was first demonstrated in a murine model of cisplatin nephrotoxicity, where NGAL was detectable in the urine before other biochemical indicators of kidney injury. 10 Clinical studies investigating the association of urinary NGAL with nephrotoxins have been limited mainly to intravenous contrast agents. In children and adults undergoing cardiac catheterization with angiography, urinary NGAL is an early predictor of contrastinduced nephropathy. 11, 12 Similar to our results, NGAL level is also elevated following contrast administration in patients who do not develop a significant increase in serum creatinine level. 13, 14 Nephrotoxic injury caused by cisplatin and cyclosporine exposure also may be identified by urinary NGAL concentration. 15, 16 In a recent study, chronic NSAID exposure in adults with spondyloarthritis was associated with a significant rise in urinary NGAL. 17 Critically ill children are exposed to numerous nephrotoxic medications, which contribute to 16%-25% of all cases of AKI. [18] [19] [20] The development of AKI is associated with longer hospital stay, prolonged mechanical ventilation, and increased patient mortality. Furthermore, increasing severity of AKI confers an incremental increase in the risk of adverse outcomes. [21] [22] [23] Thus, considering that there are no effective treatments to reverse AKI, early identification and prompt management of nephrotoxic medication-associated kidney injury are paramount. Our results indicate that urinary NGAL can detect NSAID-mediated tubular injury at the initial stage of kidney injury, when structural damage has occurred despite any appreciable increase in serum creatinine level.
In this study, the diagnostic accuracy of urinary NGAL in identifying children who received NSAIDs was excellent, with an AUC of 0.95-0.96 at 24-48 hours after NSAID administration. Moreover, urinary NGAL accurately discriminated between children receiving 1 dose of NSAIDs vs those receiving multiple doses of NSAIDs. Urinary NGAL levels continued to increase in patients receiving multiple doses of NSAIDs, but decreased in the absence of repeated dosing. Taken together, these findings indicate that urinary NGAL is a highly sensitive marker for the initiation and progression of NSAIDmediated kidney injury. Considering that NSAIDs account for 2.7%-6.6% of cases of AKI in hospitalized children, 24 routine measurement of urinary NGAL concentration may be an option to mitigate renal complications in this population. For example, serial NGAL monitoring in children receiving scheduled NSAIDs could identify those with progression of subclinical kidney injury as indicated by rising NGAL levels. Such an approach would provide clinicians with a window of opportunity to proactively prevent the development of overt AKI with functional impairment. Therapeutic interventions may include dose reduction or discontinuation of nephrotoxic mediations and optimization of intravascular volume. However, because NSAIDs are usually well tolerated in healthy patients, biomarker testing likely would need to be combined with a clinical risk stratification scheme to optimize diagnostic accuracy by identifying those patients at significant risk for AKI.
Children with AKI during the study period were excluded from our analysis, to remove subjects with elevated NGAL levels associated with CPB-induced kidney injury. Thus, we were unable to assess the prognostic ability of NGAL in predicting the clinical occurrence of NSAID-induced AKI, as defined by a rise in serum creatinine level. Nonetheless, our study design permitted a targeted assessment of NSAID-induced subclinical kidney injury by studying children with NGAL levels comparable to normative values before NSAID administration. 25 Although we did not investigate clinical outcomes, the significance of our findings can be inferred by interpreting our results in the context of previous studies. At 72 hours after CPB, the median urinary NGAL level in children receiving NSAIDs was 82 ng/mL, within the previously recommended threshold range of 50-200 ng/mL to predict AKI. 5, 8, 26 Furthermore, a urinary NGAL level >100 ng/mL was measured in 16% of the children who received NSAIDs at the end of the study period, all of whom received repeated doses. Therefore, it is possible that these patients incurred a degree of nephrotoxic injury that placed them at risk for clinical AKI.
The strengths of our study include a large sample size, a prospective study design, and a rigorous protocol with frequent urine NGAL measurements. Thus, we were able to determine the precise temporal relationship between NSAID administration and urinary NGAL concentration. Urine NGAL was measured using a standardized laboratory platform that has demonstrated consistent performance and broad agreement in clinical cutoff values to predict AKI. 27 Several limitations of our study merit consideration, however. First, the study was conducted in a homogenous cohort of children undergoing cardiac surgery with minimal comorbidities, including preexisting kidney disease. We cannot be certain that our findings are generalizable to more diverse populations in which NGAL performance can be variable, such as children in the noncardiac intensive care unit. 28, 29 Compared with the pediatric population, the performance of NGAL in adults following CPB is inferior, [30] [31] [32] possibly owing to the presence of comorbid conditions. Second, the cause of AKI is often multifactorial, and we cannot exclude the possible presence of additional insults that may have affected NGAL levels. For example, some patients may have experienced acute tubular injury secondary to postoperative hemodynamic instability, which may have affected NGAL levels. However, the strong associations observed between NSAID administration and urinary NGAL levels were unlikely to be markedly affected by possible unidentified confounding variables. Third, serum creatinine levels were not obtained reliably after the study period ended. Therefore, a correlation of NGAL levels at 72 hours after CPB with subsequent development of clinical AKI could not be determined. Finally, we were unable to evaluate the association of subclinical kidney injury with patient outcomes. Previous studies in adult patients have demonstrated that subclinical kidney injury is associated with increased risk of adverse events, including longer hospital stay, initiation of renal replacement therapy, and patient death. 33, 34 Our cohort of pediatric patients represents a lower-risk population, with no deaths or need for renal replacement therapy during hospitalization. Therefore, although subclinical kidney injury has emerged as a new diagnosis with promise to improve the management of AKI, 35 the severity and clinical significance of this condition remain unknown. Further research is needed to refine the diagnosis of subclinical kidney injury by establishing NGAL thresholds that correlate with patient outcomes. 
